February 19, 2025 Advancing Neonatal Drug Development Through Collaboration At C-Path’s INC, we believe that meaningful progress in neonatal drug development...
February 19, 2025 C-Path’s eCOA Consortium Welcomes Veeva Systems and VPG Health as Newest Partners C-Path's eCOA Consortium is thrilled to welcome Veeva Systems and VPG Health...
January 28, 2025 TRxA Funding Opportunities 2025 On January 28, C-Path’s Translational Therapeutics Accelerator (TRxA)...
January 7, 2025 Inclusion in neurological research: empowering people living with neurological diseases The value of involving people living with diseases in the research process is increasingly recognized...
December 12, 2024 Investigating item response theory model performance in the context of evaluating clinical outcome assessments in clinical trials Item response theory (IRT) models are an increasingly popular method choice for...
November 27, 2024 A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials...
October 8, 2024 Flexible approaches to eCOA administration in clinical trials: The site perspective Estelle Haenel, Celeste A. Elash, Katie Garner, Megan Turner, Scottie KernAbstract Electronic Clinical Outcome Assessment (eCOA) C
October 1, 2024 The AMR Accelerator Calls to Action: European Capacity for Antibiotic R&D Requires Long-term Funding Note: You are reading this information because Critical Path Institute is a partner of both ERA4TB and Unite4TB.
September 19, 2024 C-Path’s PKD Outcomes Consortium Receives BAA Award for Project to Advance Drug Development Tools for Autosomal Dominant Tubulointerstitial Kidney Disease C-Path is thrilled to announce its PKDOC has been awarded...
August 1, 2024 Advancing Rare Disease Measurement With The Rare Disease COA Resource It is estimated that more than 350 million people worldwide live with a rare disease.
